{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:28:56Z","timestamp":1787711336714,"version":"build-2784847793"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute for Health Research UK Health Technology Assessment Programme"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ophtha.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T18:39:38Z","timestamp":1538851178000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Intralesional Macular Atrophy in Anti\u2013Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial"],"prefix":"10.1016","volume":"126","author":[{"given":"Clare","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-2615","authenticated-orcid":false,"given":"Chris A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-9487","authenticated-orcid":false,"given":"Barnaby C.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbra","family":"Hamill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-1158","authenticated-orcid":false,"given":"Simon P.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ophtha.2018.07.013_bib1","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1016\/j.ophtha.2018.07.013_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: two-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"201312","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2018.07.013_bib3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.07.013_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the Comparison of Age-related Macular Degeneration Treatments Trials Research Group","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","article-title":"Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"119","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"issue":"78","key":"10.1016\/j.ophtha.2018.07.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A\u00a0randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ophtha.2018.07.013_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/bjo.84.3.244","article-title":"Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?","volume":"84","author":"McClure","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.07.013_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0161-6420(91)32186-9","article-title":"The Wisconsin age-related maculopathy grading system","volume":"98","author":"Klein","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib10","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2018.07.013_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib12","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.07.013_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-015-0015-6","article-title":"Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration","volume":"1","author":"Dhrami-Gavazi","year":"2015","journal-title":"Int J Ret Vit"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017338496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017338496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:03Z","timestamp":1758982083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017338496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0161642017338496"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.07.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intralesional Macular Atrophy in Anti\u2013Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}